Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation
International Journal of Drug Delivery Technology · 04.06.2026 · 16 (46s)
DOI: 10.25258/ijddt.16.46s.52 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 04.06.2026. Verfasst von Naga Bharathi. MARNI und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Back ground: Gout pathogenesis involves hyperuricemia mediated by xanthine dehydrogenase (XDH) over activity.
Purpose
Although Cleome gynandra is traditionally utilized for inflammatory disorders, its specific anti-gout mechanisms remain scientifically uncharacterized. Material and Methods: This study investigated six major phytoconstituents for XDH (PDB: 1N5X) binding affinity using CB-Dock2, followed by in vitro enzyme inhibition assays and in vivo hyperuricemia models to establish mechanistic action and therapeutic efficacy.
Results
Phytosterols exhibited the strongest binding affinity (−10.1 kcal/mol), surpassing allopurinol (−6.1 kcal/mol). ADMET analysis (ADMET lab 2.0) confirmed drug-likeness, though phytosterols showed poor human intestinal absorption (HIA = 0.002) due to high LogP (7.9). In vitro xanthine oxidase (XO) inhibition assay revealed the aqueous extract significantly inhibited XO (IC₅₀ = 48.7 µg/mL), correlating with high glucocapparin (2.1–2.9 mg/g) and quercetin (1.7–2.1 mg/g) content (based on published HPLC data). In vivo, gout was induced in chicks (n = 3/group) using sodium bicarbonate (5g/L). Treatment with aqueous extract (100 mg/kg, p.o.) significantly reduced serum uric acid from 27.19 ± 1.83 mg/dL (gout control) to 18.87 ± 0.94 mg/dL (p < 0.01) by day 21, comparable to allopurinol (50 mg/kg).
Conclusion
Joint swelling and visceral urate deposits were markedly reduced. ALT, AST, and WBC levels normalized, confirming safety. Although phytosterols showed strong in-silico binding, their poor bioavailability limits therapeutic relevance. In contrast, glucocapparin—present in the active aqueous extract—exhibits moderate docking affinity (−7.6 kcal/mol), high HIA (0.839), and correlates with XO inhibition and uric acid reduction. These findings support C. gynandra as a promising natural candidate for gout management.
Zitieren
APA
MARNI, N. B., GEDELA, M., M, I., BOTCHA, D. P., KORUPOLU, H. L., & KARANAM, S. R. (2026). Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation. International Journal of Drug Delivery Technology, 16(46s). https://doi.org/10.25258/ijddt.16.46s.52
Vancouver
MARNI NB, GEDELA M, M I, BOTCHA DP, KORUPOLU HL, KARANAM SR. Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation. International Journal of Drug Delivery Technology. 2026;16(46s). doi:10.25258/ijddt.16.46s.52
BibTeX
@article{MARNI2026,
author = {MARNI, Naga Bharathi. and GEDELA, Madhuri. and M, Indu. and BOTCHA, Delhi Priya and KORUPOLU, Hema Latha and KARANAM, Sridevi Ranjitha.},
title = {Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {46s},
doi = {10.25258/ijddt.16.46s.52}
}
EUVIMED